Genentech, Inc Patent Portfolio Statistics

Genentech, Inc.

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Genentech, Inc. look like?

Total Applications: 2,052
Granted Patents: 889
Grant Index 55.84 %
Abandoned/Rejected Applications: 703 (44.16%)
In-Process Applications: 458
Average Grant Time: 3.63 Years
Average Office Actions: 2.05

Which Technology Area Genentech, Inc. is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1644 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 213
1642 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 182
1643 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 160
1646 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 146
1647 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 130

How many patents are Genentech, Inc. filing every year?

Year Total Applications
2022 0*
2021 24*
2020 31
2019 35
2018 22

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Genentech, Inc. in USPTO?

Publication number: US20220024945A1
Application number: 17/449,398

Abstract:
Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Publication date: 2022-01-27
Applicant: Genentech, Inc.
Inventors: Mark Zak


Publication number: US20220002437A1
Application number: 17/483,281

Abstract:
The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.

Publication date: 2022-01-06
Applicant: Genentech, Inc.
Inventors: Jeong Kim


Publication number: US20210401392A1
Application number: 17/473,495

Abstract:
The present disclosure relates to techniques for segmenting tumors with positron emission tomography (PET) using deep convolutional neural networks for image and lesion metabolism analysis. Particularly, aspects of the present disclosure are directed to obtaining a PET scans and computerized tomography (CT) or magnetic resonance imaging (MRI) scans for a subject, preprocessing the PET scans and the CT or MRI scans to generate standardized images, generating two-dimensional segmentation masks, using two-dimensional segmentation models implemented as part of a convolutional neural network architecture that takes as input the standardized images, generating three-dimensional segmentation masks, using three-dimensional segmentation models implemented as part of the convolutional neural network architecture that takes as input patches of image data associated with segments from the two-dimensional segmentation mask, and generating a final imaged mask by combining information from the two-dimensional segmentation masks and the three-dimensional segmentation masks.

Publication date: 2021-12-30
Applicant: Genentech, Inc.
Inventors: Bengtsson Gustav Nils Thomas


How are Genentech, Inc.’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/449,398 Therapeutic Compounds And Compositions, And Methods Of Use Thereof OPAP Central, Docket
17/483,281 Methods Of Treating Cancers Using Pd-1 Axis Binding Antagonists And Taxanes Application Undergoing Preexam Processing 1644
17/473,495 Deep Convolutional Neural Networks For Tumor Segmentation With Positron Emission Tomography Docketed New Case – Ready for Examination OPAP Central, Docket
17/392,943 Optimized Antibody Compositions For Treatment Of Ocular Disorders Application Undergoing Preexam Processing 1647
17/443,780 Subcutaneous Anti-Her2 Antibody Formulations And Uses Thereof Application Undergoing Preexam Processing OPAP Central, Docket